文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

肌肉减少性肥胖与癌症患者结局

Sarcopenic Obesity and Outcomes for Patients With Cancer.
PubMed 文献 · JAMA Netw Open · 2024-06-03
一句话结论在实体瘤患者中,按ESPEN-EASO标准诊断的肌肉减少性肥胖与更差的总生存、更差生活质量和更高ICU入住风险相关,低握力是唯一与总生存相关的诊断组分。

这项前瞻性队列研究纳入6790例实体瘤患者,按ESPEN-EASO共识标准分为肌肉减少性肥胖(SO)组和非SO组,主要终点为总生存(OS),次要终点为生活质量和ICU入住风险。全队列SO患病率为4.36%(296/6790),肥胖亚组为14.98%(296/1976),SO患病率随年龄增长而升高。中位随访6.83年期间2103例死亡,Cox回归显示SO与更低OS独立相关(HR 1.54,95%CI 1.23-1.92),男性和女性中均可见(男性HR 1.51,95%CI 1.09-2.10;女性HR 1.53,95%CI 1.12-2.07)。SO还与更差生活质量和更高ICU入住风险相关(OR 2.39,95%CI 1.06-5.29),诊断组分中仅低握力与不良OS相关(HR 1.15,95%CI 1.04-1.28)。

要点

  • 实体瘤患者中按ESPEN-EASO标准诊断的SO与更低OS独立相关(HR 1.54,95%CI 1.23-1.92),男性和女性中均可见(男性HR 1.51,95%CI 1.09-2.10;女性HR 1.53,95%CI 1.12-2.07)。
  • SO与更高ICU入住风险相关(OR 2.39,95%CI 1.06-5.29),并与更差生活质量相关。
  • 全队列SO患病率为4.36%(296/6790),肥胖亚组为14.98%(296/1976),SO患病率随年龄增长而升高。
  • SO各诊断组分中,低握力是唯一与不良OS相关的组分(HR 1.15,95%CI 1.04-1.28)。

适用人群与场景

  • 2013年5月7日起诊断的实体瘤患者,末次随访2022年6月30日,按ESPEN-EASO标准分为SO组和非SO组。

诊断标准与关键阈值

  • 采用欧洲临床营养与代谢学会(ESPEN)和欧洲肥胖研究学会(EASO)提出的肌肉减少性肥胖(SO)共识定义和诊断标准(ESPEN-EASO标准)。

研究设计与关键结果

  • 前瞻性队列研究纳入6790例实体瘤患者(平均[SD]年龄59.64[10.77]岁;女性3489例[51.4%]),按ESPEN-EASO标准分为SO组和非SO组,主要终点为OS,次要终点为生活质量和ICU入住风险。
  • 全队列SO患病率为4.36%(296/6790),肥胖亚组为14.98%(296/1976);SO患病率随年龄增长而升高。
  • 中位(IQR)随访6.83(5.67-7.04)年期间2103例死亡;Cox回归显示SO与更低OS独立相关(HR 1.54,95%CI 1.23-1.92),男性和女性中均可见(男性HR 1.51,95%CI 1.09-2.10;女性HR 1.53,95%CI 1.12-2.07)。
  • SO与更差生活质量和更高ICU入住风险相关(OR 2.39,95%CI 1.06-5.29)。
  • SO诊断组分中,低握力是唯一与不良OS相关的组分(HR 1.15,95%CI 1.04-1.28)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ESPEN-EASO算法似乎是识别癌症相关SO的适用工具,SO代表这些患者中的主要临床并发症和不良结局风险相关因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) have recently proposed a consensus definition and diagnostic criteria for sarcopenic obesity (SO).

OBJECTIVE: To implement the ESPEN-EASO diagnostic algorithm to investigate the prevalence of SO and its association with outcomes in patients with solid tumor cancers, with particular regard to associations among SO, overall survival (OS), and patient quality of life (QoL).

DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study included patients diagnosed with solid tumor starting in May 7, 2013, with the last follow-up on June 30, 2022. Patients with solid tumors were categorized into SO and non-SO groups according to ESPEN-EASO criteria. The primary outcome was OS and the secondary outcomes included patient QoL and risk of intensive care unit (ICU) admission. Data were analyzed from June to December 2023.

RESULTS: A total of 6790 patients were included in the study (mean [SD] age, 59.64 [10.77] years; 3489 were female [51.4%]). The prevalence of SO was 4.36% (296 of 6790) in the whole cohort and 14.98% (296 of 1976) in the subgroup with obesity. SO prevalence increased with age. During a median (IQR) follow-up period of 6.83 (5.67-7.04) years, 2103 patients died. Cox regression analysis indicated that SO was independently associated with lower OS (hazard ratio [HR], 1.54; 95% CI, 1.23-1.92), which was observed in both men (HR, 1.51; 95% CI, 1.09-2.10) and women (HR, 1.53; 95% CI, 1.12-2.07). SO was also associated with poorer QoL and higher risk of ICU admission (odds ratio, 2.39; 95% CI, 1.06-5.29). Among the diagnostic components of SO, low hand grip strength (HGS) was the only SO component associated with poor OS (HR, 1.15; 95% CI, 1.04-1.28).

CONCLUSIONS AND RELEVANCE: This cohort study of SO found that SO was significantly associated with lower OS, poorer QoL, and higher risk of ICU admission. Weak HGS, 1 of the diagnostic conditions, was the only component of SO associated with OS. The ESPEN-EASO algorithm appears to be an applicable tool to identify cancer-associated SO, which represents a major clinical complication and factor associated with risk for poor outcomes in these patients.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Liu C, Liu T, Deng L, et al. Sarcopenic Obesity and Outcomes for Patients With Cancer. JAMA Netw Open. 2024. PMID: 38874924. doi:10.1001/jamanetworkopen.2024.17115

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。